Staging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic Airspaces
Recruiting · NCT07066813 · Observational (researchers observe without assigning treatment)
View the official record on ClinicalTrials.gov →What this trial is about
The goal of this observational study is to determine the most accurate tumor size measurement method for T-staging and prognostic assessment in lung cancer with cystic airspaces (LCCA). The main questions it aims to answer are: * What is the optimal T-staging approach for accurately classifying lung cancer with cystic airspaces （LCCA) and predicting patient outcomes? * How do imaging features of cystic lesions correlate with their pathological characteristics? * What is the relationship between imaging features of cystic airspace-associated lesions and patient prognosis? * Can optimizing the T-staging method improve clinical decision-making in patients with LCCA?
Who can take part
Inclusion criteria
- Histologically confirmed non-small cell lung cancer (NSCLC), as verified by biopsy or postoperative pathological examination;
- Patients who have undergone surgical lung resection;
- Patients with complete preoperative chest CT imaging data;
- Preoperative chest CT showing a well-defined gas-containing (air-filled) cystic component within the tumor.
Exclusion criteria
- History of pulmonary diseases that could produce cystic lung lesions (e.g., tuberculosis, pulmonary fungal infections, bullae, emphysema, Lymphangioleiomyomatosis \[LAM\], or Birt-Hogg-Dubé \[BHD\] syndrome);
- Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment;
- Patients with concurrent other malignancies;
- Patients with missing or poor-quality preoperative chest CT imaging data.
Where it is running
1 location listed.
- The Second Xiangya Hospital of Central South University - Changsha, Hunan, China